July 2, 2020

BioStem Technologies today announced the submission of applications for three of its dehydrated placental membrane allograft products to the Centers for Medicare and Medicaid Services (CMS), in process to be granted Q-Codes.
Read MoreRead More

June 26, 2020

BioStem Life Sciences has added California and Maryland to its list of tissue bank licenses issued by the individual state’s Department of Health.
Read MoreRead More

April 29, 2020

The Company announced that it embarked on a new initiative to define its two distinct business pillars, BioStem Technologies and BioStem Life Sciences. The new strategic focus of BioStem Technologies is to identify, develop and market the life changing regenerative biologics, formally spearheaded by BioStem Life Sciences. This includes an all new biologic therapeutic pipeline focused on Acute Respiratory Distress Syndrome (ARDS) and Osteoarthritis (OA). BioStem Technologies will also assume the sales and distribution of the RHEO™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC brands.
Read MoreRead More

April 15, 2020

Like most organizations around the world, BioStem has been closely monitoring the COVID-19 pandemic and its impact on patients, healthcare professionals, and our community. We continue to monitor and respond to this rapidly changing situation based on updates and recommendations from the CDC and local health officials, so please visit this page for updates.
Read MoreRead More

Subscribe To Our Newsletter

To stay up to date on all of our news, products, and achievements, please subscribe to our newsletter

Contact Information

(954) 380-8342

2836 Center Port Circle
Pompano Beach, FL 33064




© 2020 BioStem Technologies. All Rights Reserved. Use of this site is subject to certain Terms Of Use and Privacy Policy.
For screen reader problems with this website, please call (954) 380-8342 for assistance.